A Multicenter, Randomized, Open Label, Pilot Study to Assess the Possibility of Concomitant Treatment of HCV/HIV co Infection With Peg-Interferon + Ribavirin, and Lopinavir/r as a Single Antiretroviral Agent.

Trial Profile

A Multicenter, Randomized, Open Label, Pilot Study to Assess the Possibility of Concomitant Treatment of HCV/HIV co Infection With Peg-Interferon + Ribavirin, and Lopinavir/r as a Single Antiretroviral Agent.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2013

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors; Peginterferon; Ribavirin
  • Indications Hepatitis C; HIV infections
  • Focus Therapeutic Use
  • Acronyms PEKARI
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top